Hetero`s Generic Ospemifene Receives Approval in the U.S.
ROSEMONT, PA, Aug. 13, 2019 /PRNewswire/ - Duchesnay USA, a pharmaceutical company that specializes in women's health, is pleased to announce the launch of the new Osphena® (ospemifene) website. The website was redone to reflect the addition of Osphena®'s second FDA-approved indication — moderate to severe vaginal dryness due to menopause — to its original indication for the treatment of moderate to severe dyspareunia (painful intercourse) due to menopause.
Shionogi Divests and exclusively licenses its paediatric products to Concordia Pharmaceuticals Inc
Duchesnay, a specialty pharma company with a long-standing commitment to women's health, has acquired exclusive U.S. and Canadian rights to market and distribute Osphena® (ospemifene) from Shionogi Inc. Osphena® is the only oral, non-hormonal prescription medication indicated for the treatment of moderate to severe dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The acquisition is effective immediately.
Duchesnay, a specialty pharma company with a long-standing commitment to women's health, has acquired exclusive U.S. and Canadian rights to market and distribute Osphena® (ospemifene) from Shionogi Inc. Osphena® is the only oral, non-hormonal prescription medication indicated for the treatment of moderate to severe dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The acquisition is effective immediately.
Endoceutics should have a U.S. distribution partner for Intrarosa, a newly FDA-approved treatment for vulvovaginal atrophy in postmenopausal women, before the end of the year, says founder and CEO Fernand Labrie.
Bridgepoint Capital has sold Quotient Clinical to GHO Capital, a fund backed by Quintiles founder Dennis Gillings.
Shionogi`s Senshio (Ospemifene) Approved in Europe for Vulvovaginal Atrophy